ASCO presentation: Selumetinib in second-line non-small cell lung cancer.What we already know: Last September, Array partner AstraZeneca (AZN) announced top-line results from the phase II study, in which the combination of selumetinib plus docetaxel demonstrated a "numerically greater increase" in survival compared to docetaxel alone. Key questions: The survival trend favoring selumetinib wasn't statistically significant but full details on the drug's efficacy, including PFS and response rate endpoints, will be presented at ASCO.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts